These anti-androgen drugs have been shown to be effective and safe for the treatment of prostate cancer for decades, and are promising for mitigating symptom severity in patients with SARS-CoV-2 by downregulating TMPRSS2 levels. Here, TMPRSS2 is linked to Familial prostate cancer.